XML 145 R132.htm IDEA: XBRL DOCUMENT
v3.22.4

SEGMENT INFORMATION - Revenues by Product Category (Details) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 USD ($) product | Dec. 31, 2021 USD ($) product | Dec. 31, 2020 USD ($) product
Revenue from External Customer [Line Items] |  |  |
Number of products represented of total revenue | product | 10 | 10 | 10
Revenues | $ 8,124 | $ 8,434 | $ 8,027
Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 3,676 | 3,763 | 3,680
Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,872 | 1,903 | 1,566
OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,611 | 1,532 | 1,430
Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 887 | 1,144 | 1,248
Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 78 | 92 | 103
Salix |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 2,090 | 2,074 | 1,904
Salix | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 2,090 | 2,066 | 1,899
Salix | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Salix | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Salix | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Salix | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 8 | 5
International |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 988 | 1,166 | 1,181
International | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 279 | 259 | 255
International | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
International | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 151 | 136 | 112
International | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 527 | 738 | 775
International | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 31 | 33 | 39
Solta Medical |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 300 | 308 | 253
Solta Medical | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Solta Medical | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 300 | 308 | 253
Solta Medical | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Solta Medical | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Solta Medical | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Diversified Products |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 978 | 1,121 | 1,274
Diversified Products | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 826 | 924 | 1,020
Diversified Products | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Diversified Products | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 7 | 7 | 7
Diversified Products | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 120 | 167 | 219
Diversified Products | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 25 | 23 | 28
Bausch + Lomb |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 3,768 | 3,765 | 3,415
Bausch + Lomb | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 481 | 514 | 506
Bausch + Lomb | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,572 | 1,595 | 1,313
Bausch + Lomb | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,453 | 1,389 | 1,311
Bausch + Lomb | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 240 | 239 | 254
Bausch + Lomb | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | $ 22 | $ 28 | $ 31
Revenues | Product Concentration Risk | Customer, Top Ten Products |  |  |
Revenue from External Customer [Line Items] |  |  |
Concentration risk, percentage | 49.00% | 43.00% | 41.00%

X
- Definition Concentration Risk, Number Of Products + References No definition available. + Details
Name: | bhc_ConcentrationRiskNumberOfProducts
Namespace Prefix: | bhc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_DeviceProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OtherRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |